Publication | Open Access

Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial

VaccinationVaccine SafetyVaccine DevelopmentImmunologyMedicineVaccine ResearchCovid-19